TYME News and Press, Tyme Technologies Inc. From 01/04/21

Ocugen (OCGN) +127%.The9 Limited (NCTY +62% after signing a legally binding cooperation and investment term sheet.Bionano Genomics (BNGO +44% on publishing study on Autism Risk Genes.ViewRay (VRAY +23% on preliminary Q4 results.AirNet Technology (ANTE +28%&#...

Today, we revisit Tyme Technologies, for the first time in nearly a year. This intriguing oncology play is way under analysts' price targets but the shares have done little in 2020. We update our investment thesis on this $1 small-cap stock in the paragraphs below. For furth...

SM-88 is an oral, investigational cancer metabolism-based therapy that has demonstrated clinical responses across 15 different cancers New oral approach aimed at disrupting cancer metabolism in metastatic pancreatic cancer; ~ 58,000 cases annually in U.S. alone In clinical tri...

Tyme Technologies ([[TYME]] +6.4%) has appointed Richie Cunningham as the company's new Chief Executive Officer, effective November 24.Steve Hoffman will remain in the role of Chairman of the board of directors and continue as the Company’s Chief Science Officer, af...

Steve Hoffman, TYME’s Long-Time Chairman and Chief Executive Officer, to Remain Chairman and Chief Science Officer Richie Cunningham, to Succeed Steve Hoffman as Chief Executive Officer Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechno...

TYME revealed potential new oral therapy, TYME-19, in the fight against COVID-19 based on its cancer metabolism research program TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer PanCAN enrolling patients i...

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Jefferies Virtual Global Healthcare Conference on November 17-19. In one-on-one sessions, ...

I am taking a "Bamboo Investment" approach to Tyme Technologies in anticipation the company's pivotal trial data will confirm SM-88's ability to be a game changing oncology agent. Tyme is matching SM-88 up against pancreatic cancer in the 2nd and 3rd lines of treatment. If approved, S...

Tyme has a solid product candidate in pancreatic cancer. The company has no debt, strong IP, good insider interest. Current price is a little on the higher side for my comfort. This article was posted for TPT subscribers earlier this month. For further details see: T...

Marinus Pharmaceuticals (NASDAQ: MRNS )   +61%  after ganaxolone successful in pivot study in rare type of epilepsy. More news on: Marinus Pharmaceuticals, Inc., Plus Therapeutics, Inc., Tiziana Life Sciences PLC, Stocks on the move, , Read more ...